Moleculin Biotech (Moleculin Biotech) Total Stockholders Equity : $26.07 Mil (As of Dec. 2023)

View and export this data going back to 2016. Start your Free Trial

What is Moleculin Biotech Total Stockholders Equity?

Moleculin Biotech's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $26.07 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Moleculin Biotech's Book Value per Share for the quarter that ended in Dec. 2023 was $11.70. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Moleculin Biotech's Debt-to-Equity for the quarter that ended in Dec. 2023 was 0.02.

Moleculin Biotech Total Stockholders Equity Historical Data

The historical data trend for Moleculin Biotech's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Moleculin Biotech Total Stockholders Equity Chart

Moleculin Biotech Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Stockholders Equity

Get a 7-Day Free Trial

15.57

17.76

78.99

52.19

26.07

Moleculin Biotech Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Total Stockholders Equity	Get a 7-Day Free Trial															52.19	45.68	40.27	35.14	26.07

Moleculin Biotech (NAS:MBRX) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Moleculin Biotech's Book Value per Share for the quarter that ended in Dec. 2023 is

Book Value per Share	=	(Total Stockholders Equity	-	Preferred Stock)	/	Shares Outstanding (EOP)
	=	(26.073	-	0)	/	2.22752
	=	11.70

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Moleculin Biotech's Debt-to-Equity for the quarter that ended in Dec. 2023 is

Debt-to-Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.1	+	0.474)	/	26.073
	=	0.02

Moleculin Biotech Total Stockholders Equity Related Terms

Thank you for viewing the detailed overview of Moleculin Biotech's Total Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Moleculin Biotech (Moleculin Biotech) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Moleculin Biotech Inc (NAS:MBRX) » Definitions » Total Stockholders Equity

Comparable Companies

Traded in Other Exchanges

MOLA:Germany

Address

5300 Memorial Drive, Suite 950, Houston, TX, USA, 77007

Website

https://www.moleculin.com

Moleculin Biotech Inc is a clinical-stage pharmaceutical company with a focus on the treatment of highly resistant cancers and viruses through the development of its drug candidates. The company has three core technologies: Annamycin which is a next-generation anthracycline; Immune/Transcription Modulators, of which WP1066 is a member; and Metabolism/Glycosylation Inhibitors, of which WP1122 is a member.

Executives

Jonathan P. Foster	officer: Exec. Vice President and CFO	2450 SOUTH SHORE BLVD., SUITE 402, LEAGUE CITY TX 77573
Walter V Klemp	director, 10 percent owner, officer: Chairman and Acting CEO	1415 WEST LOOP NORTH, HOUSTON TX 77055
Robert E. George	director	2575 W. BELLFORT, SUITE 333, HOUSTON TX 77054
Joy Yan	director	10975 NORTH TORREY PINES ROAD, LA JOLLA CA 92037
Elizabeth Cermak	director	1414 RALEIGH ROAD, SUITE 400, CHAPEL HILL NC 27517
Waldemar Priebe	10 percent owner	2575 W. BELLFORT, SUITE 333, HOUSTON TX 77054
John M Climaco	director	PO BOX 326, PARK CITY UT 84060
Jacqueline Northcut	director	2575 W. BELLFORT, SUITE 333, HOUSTON TX 77054
Donald H Picker	10 percent owner, officer: President and COO
Michael D Cannon	director	C/O SICOR INC, 19 HUGHES, IRVINE CA 92618-1902
Louis Jr Ploth	officer: Chief Financial Officer	2408 TIMBERLOCH PLACE STE B1, WOODLANDS TX 77380